MorphoSysDE0006632003MORMOR
![MorphoSys logo](https://static.getquin.com/logos_v2/light/DE0006632003.png)
Financials
Market Cap
$2.77B5Y beta
0.77EPS (TTM)
-$13.71Free Float
2.13MRevenue (TTM)
$220.58MEBITDA (TTM)
-$467.77MFree Cashflow (TTM)
-$326.04MPricing
Analyst Ratings
The price target is $60.70 and the stock is covered by 11 analysts.
Buy
4
Hold
7
Sell
0
Information
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.